Does Medicare cover Mounjaro?
Short answer: For type 2 diabetes, yes — Mounjaro (tirzepatide) is covered by most Part D plans with plan-specific terms. For weight loss without diabetes, the answer runs through the same molecule's other product: Zepbound, covered at $50/month under the Bridge program (KwikPen form only) if you meet the BMI tiers.
Program facts last verified against CMS: July 21, 2026
Mounjaro vs. Zepbound: same drug, different doors
Both are tirzepatide from Eli Lilly. Mounjaro carries the type 2 diabetes indication; Zepbound carries weight management and sleep-apnea indications. Medicare coverage follows the indication: diabetes → Mounjaro through your Part D plan; weight-loss eligibility (BMI tiers, no diabetes) → Zepbound through the Bridge at $50; moderate-to-severe sleep apnea → Zepbound through Part D under its OSA indication.
The paths have different cost mechanics too: Part D coverage (Mounjaro) counts toward your out-of-pocket cap and accepts Extra Help; the Bridge (Zepbound) is a flat $50 that does neither. Which is cheaper for you across a year depends on your other drug spending — our cost comparison guide walks the math.
Take the 2-minute eligibility check →
Common questions
Can I get Mounjaro under the $50 Bridge?
No — the Bridge covers Zepbound (the weight-management tirzepatide product) in KwikPen form, not Mounjaro. With a diabetes diagnosis, Mounjaro runs through your Part D plan instead.
I have diabetes AND want weight loss. Which product am I on?
The diabetes diagnosis routes you to the Part D path — typically Mounjaro or another diabetes-indicated GLP-1. That's usually favorable: Extra Help applies and payments count toward the cap. The weight-loss effects come with the therapy either way.
Does Medicare cover Mounjaro without prior authorization?
Most plans require prior authorization for GLP-1s, and some add step therapy. Your prescriber's office handles this routinely — plan formularies list the specifics.
Related
Program-fact sources: CMS — Medicare GLP-1 Bridge · KFF